Northern Capital Management LLC grew its position in shares of Johnson & Johnson (NYSE:JNJ) by 10.2% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,441 shares of the company’s stock after buying an additional 3,090 shares during the quarter. Johnson & Johnson accounts for approximately 1.3% of Northern Capital Management LLC’s investment portfolio, making the stock its 16th biggest holding. Northern Capital Management LLC’s holdings in Johnson & Johnson were worth $4,348,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. K.J. Harrison & Partners Inc raised its holdings in shares of Johnson & Johnson by 33.2% in the 3rd quarter. K.J. Harrison & Partners Inc now owns 62,011 shares of the company’s stock worth $8,062,000 after purchasing an additional 15,451 shares during the period. Parametrica Management Ltd raised its holdings in shares of Johnson & Johnson by 57.9% in the 3rd quarter. Parametrica Management Ltd now owns 4,100 shares of the company’s stock worth $533,000 after purchasing an additional 1,503 shares during the period. Victory Capital Management Inc. raised its holdings in shares of Johnson & Johnson by 40.1% in the 3rd quarter. Victory Capital Management Inc. now owns 222,470 shares of the company’s stock worth $28,924,000 after purchasing an additional 63,633 shares during the period. Mosaic Family Wealth LLC raised its holdings in shares of Johnson & Johnson by 10.4% in the 3rd quarter. Mosaic Family Wealth LLC now owns 12,351 shares of the company’s stock worth $1,606,000 after purchasing an additional 1,159 shares during the period. Finally, Intact Investment Management Inc. raised its holdings in shares of Johnson & Johnson by 0.9% in the 3rd quarter. Intact Investment Management Inc. now owns 67,400 shares of the company’s stock worth $8,761,000 after purchasing an additional 600 shares during the period. 65.70% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Johnson & Johnson (NYSE JNJ) opened at $145.76 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $110.76 and a 1-year high of $146.42. The stock has a market cap of $391,587.16, a price-to-earnings ratio of 20.41, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the previous year, the firm posted $1.68 EPS. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a yield of 2.31%. Johnson & Johnson’s payout ratio is 58.33%.
JNJ has been the topic of a number of research reports. Jefferies Group lifted their price target on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 16th. UBS Group reaffirmed a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a report on Saturday, September 30th. Cowen set a $147.00 price target on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Friday, October 6th. Citigroup lifted their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a report on Monday, October 23rd. Finally, Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $147.14 price target on the stock in a report on Wednesday, December 20th. Four analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $145.94.
ILLEGAL ACTIVITY WARNING: This piece was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/johnson-johnson-jnj-holdings-boosted-by-northern-capital-management-llc.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.